Clinical Trial

Effect of a Probiotic Supplement on Gut Microbiota and Glycemic Control in Patients With Type 1 Diabetes (PRODIAB)

Study acronym: PRODIAB
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 14, 2025 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.
Summary
This randomized, double-blind clinical trial aims to evaluate the effect of a probiotic supplement on gut microbiota composition and glycemic control in adults with type 1 diabetes mellitus. A secondary comparison will be made with a healthy control group. Participants will be assigned to receive either a probiotic or a placebo for 98 days. Stool samples and metabolic parameters will be collected at baseline and after the intervention period. The study seeks to better understand how modulation of the intestinal microbiota may influence glucose regulation in people with type 1 diabetes.
Trial Details
NCT Number NCT07062224
Lead Sponsor Universidad Católica San Antonio de Murcia
Conditions Diabete Type 1
Enrollment 80 participants
Start Date 2025-09
Primary Completion 2025-11 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-14